CUE BIOPHARMA INC

Discover how Cue Biopharma’s September 2026 rally, driven by a urticaria drug study and market surge, reshaped its stock’s volatile trajectory.

Explore Cue Biopharma’s latest Rule 144 sale and S‑3 registration, detailing how the biotech company balances tax‑covering shares and strategic resales while driving cancer and autoimmune drug innovation.

Form 4/A: Cue Biopharma exec Lin Shao‑Lee files private placement of $11 warrants, detailing exercise terms and stock‑price impact for biotech investors.

New CMO Dr. Dominic Borie joins Cue Biopharma to accelerate oncology biologics and boost investor confidence amid volatile valuation.

Cue Biopharma Inc is a biotechnology company pioneering innovative treatments for cancer and autoimmune diseases, offering new hope for patients and positioning itself as a leader in the field.

Cue Biopharma Inc is a biotechnology company pioneering innovative treatments for cancers and autoimmune diseases through its focus on protein biologics, immunology, and immuno-oncology.

Cue Biopharma Inc. is seeking $20 million in funding through a public offering to strengthen its financial footing and support ongoing research and development of treatments for cancers and autoimmune diseases.